Boan Biotech Wins New China Approval for Denosumab Biosimilar, Accelerates Global Push

Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in secondsShandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ) just unveiled an update. Shandong Boan Biotechnology has received approval from China’s National Medical Products Administration for a new indication of its denosumab biosimilar Boluojia, allowing its use to delay or reduce skeletal-related events in patients with bone metastases from solid tumors or multiple myeloma. This expands on Boluojia’s initial Chinese approval for giant cell tumor of bone and positions the drug as a clinically validated, guideline-recommended option with practical advantages such as subcutaneous administration and suitability for patients with renal impairment. The company is leveraging this approval to strengthen its oncology portfolio in mainland China and accelerate international expansion through a mix of in-house commercialization and partnerships, including deals covering the U.S., Southeast Asia, Latin America, Hong Kong, and Macao. With robust clinical data showing high similarity to reference drug Xgeva and a large, growing global market for denosumab therapies, the new indication is expected to enhance Boan’s competitive position and open meaningful revenue opportunities in both domestic and overseas markets. More about Shandong Boan Biotechnology Company., Limited. Class H Shandong Boan Biotechnology Co., Ltd. is a Chinese biopharmaceutical company specializing in the development and commercialization of biosimilars and innovative biologics, with a strong focus on oncology. Its portfolio includes products such as Boluojia (denosumab injection) and Boyounuo (bevacizumab injection), and it is pursuing a global strategy across China, Europe, the U.S., Japan, and emerging markets. Average Trading Volume: 6,132,000 Technical Sentiment Signal: Sell Current Market Cap: HK$3.77B For a thorough assessment of 6955 stock, go to TipRanks’ Stock Analysis page.